Cite
HARVARD Citation
Tursi, A. et al. (2022). Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert opinion on biological therapy. pp. 313-320. [Online].